The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Adaptimmune | SPONDS ADR | 00653A107 | 3,390 | 250,000 | SH | DFND | 250,000 | 0 | 0 | ||
Aurinia Pharma | Common | 05156V102 | 2,655 | 400,434 | SH | DFND | 400,434 | 0 | 0 | ||
Aveo Pharma | Common | 053588109 | 1,316 | 400,000 | SH | DFND | 400,000 | 0 | 0 | ||
Cellectis | SPONDS ADR | 15117K103 | 2,823 | 100,000 | SH | DFND | 100,000 | 0 | 0 | ||
Chiasma | Common | 16706W102 | 7,490 | 2,080,595 | SH | DFND | 2,080,595 | 0 | 0 | ||
Crispr | NAMEN AKT | H17182108 | 54,858 | 1,237,202 | SH | DFND | 1,237,202 | 0 | 0 | ||
Cymabay | Common | 23257D103 | 3,027 | 273,417 | SH | DFND | 273,417 | 0 | 0 | ||
Histogenix | Common | 43358V109 | 473 | 888,889 | SH | DFND | 888,889 | 0 | 0 | ||
Immune Design | Common | 45252L103 | 1,198 | 352,300 | SH | DFND | 352,300 | 0 | 0 | ||
Obseva | Common | H5861P103 | 7,938 | 440,000 | SH | DFND | 440,000 | 0 | 0 | ||
Paratek | Common | 699374302 | 10,047 | 1,041,131 | SH | DFND | 1,041,131 | 0 | 0 | ||
Proteon | Common | 74371L109 | 3,834 | 2,017,872 | SH | DFND | 2,017,872 | 0 | 0 | ||
Sientra | Common | 82621J105 | 52,512 | 2,199,012 | SH | DFND | 2,199,012 | 0 | 0 | ||
Sierra Oncology | Common | 82640U107 | 2,456 | 1,444,445 | SH | DFND | 1,444,445 | 0 | 0 | ||
Ultragenyx | Common | 90400D108 | 2,910 | 38,100 | SH | DFND | 38,100 | 0 | 0 | ||
Verona | SPONDS ADR | 925050106 | 11,274 | 901,943 | SH | DFND | 901,943 | 0 | 0 |